ADAP - Adaptimmune Therapeutics plc
| Previous Close | 12.41 |
| Open | 12.30 |
| Bid | 12.06 x 1000 |
| Ask | 12.07 x 1800 |
| Day's Range | 11.79 - 12.30 |
| 52 Week Range | 6.60 - 14.62 |
| Volume | 336,619 |
| Avg. Volume | 441,400 |
| Market Cap | 1.262B |
| Beta (3Y Monthly) | 0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.88 |
- GlobeNewswire•7 days ago
Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress
PHILADELPHIA and OXFORD, United Kingdom, Oct. 08, 2018 -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today.
- Barrons.com•26 days ago
3 Biotech Stocks That Big Investors Are Snatching Up
In the last two weeks, large investors have paid more than $51 million to buy more stock in three biotech firms.
- Simply Wall St.•last month
Should You Be Holding Adaptimmune Therapeutics plc (NASDAQ:ADAP) Right Now?
If you’re interested in Adaptimmune Therapeutics plc (NASDAQ:ADAP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
- GlobeNewswire•last month
Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”). Adaptimmune sold 10,000,000 ADSs at a price of $10.00 per ADS. A shelf registration statement on Form S-3 relating to the public offering of the ADSs described above was filed with the Securities and Exchange Commission (“SEC”) and became effective on July 12, 2018.
- GlobeNewswire•last month
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”), New Enterprise Associates 16, L.P., New Enterprise Associates 14, L.P. (“NEA”) and Syncona Portfolio Limited (“Syncona”), to purchase an aggregate of US$100 million of its American Depositary Shares (“ADSs”) in a registered direct offering. The transaction was completed from the company’s shelf registration at a price of $10.00 per ADS. Net proceeds of the offering will be used to advance the company’s wholly owned pipeline of SPEAR T-cell candidates through clinical trials as well as for other general corporate purposes.
Market Realist•2 months agoAdaptimmune Therapeutics Rose 21% in Week Ended August 24
On August 24, Adaptimmune Therapeutics (ADAP) stock closed at $10.25, which represents a ~21% growth from its previous week’s closing price of $8.48 on August 17.
- Zacks•2 months ago
Options Traders Expect Huge Moves in Adaptimmune (ADAP) Stock
Adaptimmune (ADAP) needs investors to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within NEXEO SOLUTIONS, Altisource Portfolio Solutions S.A, Celestica, Star Bulk Carriers, Criteo S.A, and Adaptimmune Therapeutics — Discovering Underlying Factors of Influence
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NEXEO ...
- GlobeNewswire•2 months ago
Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
PHILADELPHIA and OXFORD, United Kingdom, Aug. 15, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced a favorable review of safety data from the second dose ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ADAP earnings conference call or presentation 2-Aug-18 12:00pm GMT
Q2 2018 Adaptimmune Therapeutics PLC Earnings Call
- GlobeNewswire•2 months ago
Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update
-Dosing patients in both MAGE-A10 pilot studies in third cohort with range of one to six billion cells-. -NY-ESO program transitioned to GSK allows clinical focus on wholly owned assets-. -Guidance confirmed, ...
- ACCESSWIRE•2 months ago
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Adaptimmune Therapeutics PLC Sponsored ADR (NASDAQ: ADAP ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 ...
- GlobeNewswire•3 months ago
Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018
PHILADELPHIA and OXFORD, United Kingdom, July 26, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, will announce financial results for the Second Quarter 2018 and provide ...
- GlobeNewswire•3 months ago
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
LONDON and OXFORD, United Kingdom, July 24, 2018-- GlaxoSmithKline plc and Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced the transition of the development program ...
- Benzinga•3 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pfizer Inc. (NYSE: PFE ) stock was trading slightly ...
- GlobeNewswire•3 months ago
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
PHILADELPHIA and OXFORD, United Kingdom, July 18, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced favorable review of safety data from the second dose cohort ...
- Simply Wall St.•4 months ago
Investors Are Undervaluing Adaptimmune Therapeutics plc (NASDAQ:ADAP) By 21.72%
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Adaptimmune Therapeutics plc (NASDAQ:ADAP) as an investment opportunity by projecting itsRead More...
- ACCESSWIRE•4 months ago
Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks
Featured today on WallStEquities.com is the Biotechnology industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are four equities: Adaptimmune Therapeutics PLC (NASDAQ: ADAP), Aduro BioTech Inc. (NASDAQ: ADRO), Advaxis Inc. (NASDAQ: ADXS), and Adverum Biotechnologies Inc. (NASDAQ: ADVM).
